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formed. Based on a literature review and with input from patients, 65 potential goals were formulated as state-
ments. Consensus was considered to be reached when ≥75% of the participants agreed to include that speciﬁc
statement in the management goals. There was agreement on 42 statements. In addition to the traditional
goals concerning haematological, visceral and bonemanifestations, improvement in quality of life, fatigue and so-
cial participation, as well as early detection of long-term complications or associated diseases were included.
When applying this set of goals in medical practice, the clinical status of the individual patient should be taken
into account.
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Management goals
Delphi study
PROMs1. Introduction
Gaucher disease (GD) is a lysosomal disorder which is inherited as
an autosomal recessive condition with an estimated birth frequency of
1 in 57,000 [1]. It is caused by mutations in the GBA1 gene which en-
codes acid glucocerebrosidase; reduced activity of this enzyme leads
to a build-up of glucosylceramide – mainly in the lysosomal compart-
ment of macrophages (giving rise to the so-called ‘Gaucher cells’) [2].
Accumulation of glucosylceramide and related sphingolipids is associat-
ed with multi-system disease and diverse clinical manifestations. GD
has been classically divided into three principal types. Type 1 GD
(GD1) is mainly characterized by visceral manifestations. Signs and
symptoms include splenomegaly, hepatomegaly, thrombocytopenia,
anaemia, bone disease and fatigue. In type 2 (GD2) and type 3 (GD3)
disease there are neurological manifestations ranging from rapidly pro-
gressive neurological deterioration in GD2 leading to death in the ﬁrst
years of life, to a milder neurological phenotype in GD3 [2]. In this
study, we focused on GD1, themost common type in populations of Eu-
ropean ancestry and Ashkenazi Jews in whom it accounts for up to 95%
of patients with GD [2].
Currently, two different therapeutic approaches for the treatment of
GD1 are used: enzyme replacement therapy (ERT) and substrate reduc-
tion therapy (SRT). Intravenously administered ERT is targeted to mac-
rophages and increases the breakdown of the accumulated glycolipids;
this has proven to be very effective in the treatment of the visceral
and haematological complications of the disease [3–6]. Decreases in
splenic and hepatic size and improvement in cytopenias are usually ap-
parent after 6 months of treatment [7]. SRT reduces the amount of
glucosylceramide by inhibiting its synthesis. As an oral alternative to
ERT, its user friendliness makes this class of treatment attractive to
some patients. The ﬁrst SRT, miglustat, is approved for GD1 patients
with mild to moderate disease manifestations for whom ERT is unsuit-
able, although this varies in different countries [8]. Side effects and con-
cerns about effectiveness have limited its use [9]. Recently, eliglustat, a
second generation SRT with an improved risk/beneﬁt proﬁle has been
approved as a ﬁrst-line therapy [10].
Studies on the effectiveness of ERT/SRT traditionally use
haemoglobin concentrations, platelet counts, reduction in spleen and
liver volumes and parameters of bone disease as primary outcomemea-
sures. Hitherto, therapeutic goals have also been based on these param-
eters. The current mainstay in the assessment of treatment effect is the
set of therapeutic goals as promulgated by Pastores et al. [11]. These
goals are mainly based on data from the International Gaucher Registry,
a post-marketing drug registry sponsored by Sanoﬁ Genzyme. The po-
tential effect of ERT, as well as the time needed for this effect to be
reached, was estimated from patient data entered into this database.
Based on these calculations, goals for anaemia, thrombocytopenia,
hepatosplenomegaly, skeletal pathology, growth, lung involvement,
quality of life and biomarkers were formulated. Mean or minimal ex-
pected improvements, however, may not represent themaximum ther-
apeutic results that can be achieved in all patients. In relation to clinical
management, the goals proposed focused on outcome of therapeutic in-
tervention and not on the patient as a whole. With the passage of time
in themature era of treatment, it is clear that the traditional therapeutical., Blood Cells Mol. Diseasesgoals do not address long-term disease outcomes and associated dis-
eases (i.e. residual skeletal disease [12],monoclonal gammopathy of un-
determined signiﬁcance (MGUS) and certain types of cancer [13],
pulmonary hypertension [14], Parkinson disease (PD) [15] and meta-
bolic syndrome [16]). In recent years, the salutary effects of treatments
on the most ﬂorid initial manifestations of disease have resulted in a
modiﬁed phenotype – and a shift in focus towards those elements of
the disease that are relatively refractory to speciﬁc intervention and
complications or co-morbidities. Preliminary studies indicate that the
risk of skeletal disease or even multiple myeloma may be reduced or
even prevented with early initiation of ERT [12,17] or SRT [18], while
for other complications or associated diseases the relationship with
therapeutic intervention is not always unequivocal. However, complica-
tions and diseases that are clearly associatedwith GD1 do impact on the
life of patients and should therefore be monitored; this will improve
practice by identifying aspects requiring additional care or treatment,
and it is likely to improve our understanding of the condition in all its
complexity. While health trends latterly place increasing focus on the
patient's experience, captured by patient-reported outcome measures
(PROMs), these aspects have been little studied in ultra-rare diseases
such as GD. These PROMs reﬂect how a patient feels and functions (in
contrast to laboratory values); they are increasingly recognised as es-
sential by which to judge the overall effectiveness of any treatment
that is prescribed for patients with long-term and other conditions [19].
Taking these trends into consideration, management goals in GD1
need to be deﬁned with inclusion of those that encompass long-term
disease complications, associated diseases and PROMs. Here we report
the use of a consensus procedure among clinical experts and with
input from patients, in which speciﬁc outcomes have a central place in
recommendations for new management goals in GD1.
2. Methods
2.1. Participants
All members of the European Working Group on Gaucher Disease
(EWGGD) (n = 35) were invited to participate in this consensus
study. Patients were contacted through the European Gaucher Alliance
(EGA). The Dutch patients were contacted by telephone or through
email.
2.2. Study design
A modiﬁed Delphi procedure was used to develop group consensus
on management goals for GD1 [20]. This is a technique in which multi-
ple rounds of online surveys aim at reaching consensus on a certain sub-
ject. To serve as input for the ﬁrst survey, the study team (MB, AK, CEH)
searched for national treatment guidelines, carried out a literature re-
view and distributed a questionnaire among patients. The literature
search focused on currently usedmanagement goals aswell as potential
newmanagement goals, with speciﬁc attention to long-term complica-
tions and associated diseases. Details can be found in Appendix 1. Pa-
tients were invited to give their view on what they considered
clinically relevant management goals by ﬁlling in a questionnaire (see(2016), http://dx.doi.org/10.1016/j.bcmd.2016.10.008
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EGA. The results of the literature review and input from patients were
summarized in a background document (see Appendix 1), which was
sent to EWGGD members together with a link to the ﬁrst survey. This
survey consisted of a list of potential management goals formulated as
statements. Members who were interested to participate in the study
were asked to indicate on a 5-point Likert scale (1 = strongly disagree,
2 = disagree, 3 = neither agree nor disagree, 4 = agree, 5 = strongly
agree) whether or not they agreed to include a speciﬁc statement in
the management goals. They were encouraged to add arguments and
suggestions for additional statements. Subsequently, the responses
were analysed and the second survey was made, taking the results of
the ﬁrst round into account. The surveys were repeated until all state-
ments either reached consensus or were adequately discussed to be re-
moved. Along with the surveys, participants were provided with
anonymized results of the previous round, consisting of absolute scores
and comments.
2.3. Surveys
For the ﬁrst survey, all management goals that are currently in use
(including the therapeutic goals proposed by Pastores et al. [11]) as
well as all potential new management goals were formulated as state-
ments which were divided into 11 categories: general well-being, fa-
tigue, bleeding tendency, mobility, visceral complications, pulmonary
complications, malignancies, metabolic complications, neurological
complications, disease severity scores and biochemical markers. Fur-
thermore, each category was divided into short-term and long-term
goals.
Based on the results of the ﬁrst survey, the second survey was con-
ducted. Statements for which consensus was reached in the ﬁrst
round were presented, but not voted on in the second survey. The re-
maining statements were either removed, or amended, or repeated
without revision. Statements were removed when the study team
thought it very unlikely, based on the number of participants who
disagreed, or the comments raised by one or more participants, that
the panel would reach consensus on that statement in the second
round, even if the statement was amended. Although the removed
statementswere not voted on in the second round, theywere presented
in the survey to give participants insight into choicesmade by the study
team. When considered beneﬁcial, statements were amended based
upon the comments raised. If the arguments of the participants who
disagreed was considered insufﬁcient to either remove or revise the
statement (e.g. comments were unclear or missing, or only one partici-
pant disagreed), this statement was repeated without amendment. Ar-
guments used by the study team to amend or repeat a statement were
presented to the participants, and they were asked to vote on the
amended and repeated statements. In addition, suggestions for addi-
tional potential management goals made by participants were formu-
lated as new statements and were voted on in the second round. A
similar procedure was applied for the third survey.
2.4. Statistical considerations
A statement was included in themanagement goals if at least 75% of
the participants agreed on inclusion of that statement, and no one
disagreed [21,22].
3. Results
3.1. Patients
SeventeenDutchGD1 patients responded to the questionnaire. They
considered quality of life, bone complications, associated diseases, inde-
pendence, bone pain and fatigue the six most relevant management
goals (see also Appendix 1).Please cite this article as: M. Biegstraaten, et al., Blood Cells Mol. Diseases3.2. Consensus panel
Twenty-ﬁve of the 35 EWGGDmembers, all physicians, participated
in this consensus procedure. Other members, mostly basic scientists,
supported the initiative, but indicated that they do not have the clinical
experience that is needed to formulate management goals. Nineteen
participants completed all 3 rounds, and 6 participants completed 2
out of 3 rounds. Participants represented the following countries:
Greece, Portugal, Germany, Spain, France, Italy, Sweden, Ireland, United
Kingdom, Norway, Bosnia and Herzegovina, Russia, Poland, Israel and
Australia. They treated on average 92 patients, ranging from 2 to 600.
3.3. Overall consensus
Three rounds of surveys were needed to reach consensus on the
management goals. The ﬁrst survey consisted of 65 statements. Consen-
sus was achieved for 15 (23%) of these 65 statements. Twelve state-
ments (18%) for which no consensus could be achieved were
removed. Twenty-nine statements (45%) were rephrased according to
the suggestions of the participants. In some cases, two or more state-
ments were combined into one statement. Nine statements (14%)
were repeated without amendments. Eight additional statements
were presented in the second survey based on the suggestions of the
participants. Finally, the second survey consisted of 40 statements.
In the second survey the panel reached consensus on 4 statements
(10%), and 14 statements (35%) were removed. Nine statements (23%)
were amended based upon the comments given. Thirteen statements
(33%) were repeated without amendments. Three additional state-
ments, as proposed by the participants, were added to the third survey.
The third survey consisted of 25 statements. Consensuswas reached for
23 statements (92%) and 2 statements (8%) were removed. There was
agreement on a total of 42 statements after three surveys.
3.4. Management goals for which consensus was achieved
The consensus management goals are presented in Tables 1A, 1B
and 2. Besides a subdivision into short-term and long-term goals, it
was decided to apply an additional subdivision into goals that are ERT/
SRT related and goals that concern more general management of the
disease.
In general, the consensus panel agreed that with regard to anaemia,
bleeding tendency, bone disease, liver and spleen involvement and pul-
monary complications, physicians should aim for (near) restoration of
normal values, prevention of complications, and elimination or reduc-
tion of signs and symptoms. Also, improvement in quality of life, reduc-
tion of fatigue and normal participation in school and work activities
were considered important goals for which to strive. The panel agreed
that proper education of patients and their family members about the
nature of GD and its treatment is important, although several experts in-
dicated that they considered this not a goal as such but rather good clin-
ical practice. Consensus was reached on the statement on early
detection of signs or symptoms of GD3; however, some indicated that
patients at risk of GD3 are best identiﬁed by GBA1 analysis, and argued
that monitoring of neurologic signs and symptoms of GD3 should be
limited to those with GD3 related mutations. Finally, consensus was
achieved that early detection of malignancies, Parkinson disease/par-
kinsonism and (pre-) diabetes should be aimed for, since these condi-
tions are likely to beneﬁt from prompt initiation of appropriate
additional care or treatment.
3.5. Statements for which no consensus was achieved
The statements for which no consensus was achieved are listed in
Appendix 3. The ﬁrst survey included statements on reduction in spleen
and liver volume expressed as percentage decrease per year of treat-
ment. The panel considered these statements too speciﬁc and preferred(2016), http://dx.doi.org/10.1016/j.bcmd.2016.10.008
Table 1A
Short-term management goals for Gaucher disease type 1 – ERT/SRT related.
Category Management goals
Anaemia related
symptoms
Eliminate blood transfusion dependency (Source: Pastores et al. 2004)
Increase haemoglobin levels within 12 to 24 months to N11.0 g/dL for women and children and N12.0 g/dL for men (Source: Pastores et al., 2004)
Bleeding tendency Increase platelet counts during the ﬁrst year of treatment sufﬁciently to prevent surgical, obstetrical, and spontaneous bleeding (Source: Pastores et al.,
2004)
In patients with splenectomy: normalization of platelet count by 1 year of treatment (Source: Pastores et al., 2004)
In patients with an intact spleen: achieve platelet count of ≥100,000/mm3 by 3 years of treatment (Adapted from: Pastores et al., 2004)
Mobility Lessen bone pain that is not related to irreversible bone disease within 1 to 2 years (Adapted from: Pastores et al., 2004)
Decrease bone marrow involvement, as measured by a locally used scoring system (e.g. Bone Marrow Burden (BMB) score or Düsseldorf Gaucher Score
(DGS)) in patients without severe irreversible bone disease at baseline (Source: literature search)
Increase bone mineral density (BMD) by 2 years in adults for patients with a T-score below−2.5 at baseline (Adapted from: Pastores et al0., 2004)
Attain normal or ideal peak skeletal mass in children (Source: Pastores et al. 2004)
Normalize growth such that the height of the patient is in line with target height, based upon population standards and parental height, within 2 years of
treatment (Adapted from: Pastores et al., 2004)
Visceral
complications
Avoid splenectomy (may be necessary during life threatening haemorrhagic events) (Source: Pastores et al., 2004)
Alleviate symptoms due to splenomegaly: abdominal distension, early satiety, new splenic infarction (Source: Pastores et al., 2004)
Eliminate hypersplenism (Source: Pastores et al., 2004)
Reduce spleen volume to b2 to 8 times normal (or in absence of volume measurement tools reduce spleen size) by year 1–2, depending on baseline spleen
volume (Adapted from: Pastores et al., 2004)
Reduce the liver volume to 1.0 to 1.5 times normal (or in absence of volume measurement tools aim for normal liver size) by year 1–2, depending on
baseline liver volume (Adapted from: Pastores et al., 2004)
General well-being Improve scores from baseline of a validated quality-of-life instrument within 2 to 3 years or less depending on disease burden (Source: Pastores et al.,
2004)
Reduce fatigue (not anaemia related) as measured by a validated fatigue scoring system (Sources: input from patients, literature search)
Improve or restore physical function for carrying out normal daily activities and fulﬁlling functional roles (Source: Pastores et al., 2004)
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the statements with regard to improvement in disease severity scores
reached consensus. The three different disease severity scoring systems
that are currently available (i.e., the Severity Scoring Index (SSI) [23],
the Gaucher Disease Severity Score Index – Type 1 (GauSSI-I) [24],
and the Gaucher disease severity scoring system (GD1-DS3) [25])
have all been insufﬁciently validated for general use. Also, no consensus
was reached on the statementswith respect to decreases in serum/plas-
ma biomarkers (i.e., chitotriosidase [26], chemokine ligand 18/pulmo-
nary and activation-regulated chemokine (CCL18/PARC) [27] and
ferritin concentrations [28]). Some panel members were very clear in
their opinion that changes in biomarkers should not be used as a goal,
and it was argued that the relationship between biomarkers and clinical
consequences of GD are still insufﬁciently clear. At the same time, others
indicated that chitotriosidase is a very useful biomarker in the follow-up
of patients. Thirdly, no consensus was achieved for statements on con-
ditions that are associated with but not speciﬁc for GD1, such as ironTable 1B
Long-term management goals for Gaucher disease type 1 – ERT/SRT related.
Category Management goals
Anaemia related
symptoms
Maintain improved haemoglobin values achieved after the
Bleeding tendency Maintain platelet count of ≥100,000/mm3 (Adapted from:
Reduce increased bleeding tendency, whether caused by lo
(Sources: input from patients, national guidelines, literatur
Mobility Prevent bone complications: avascular necrosis, bone crise
Pastores et al., 2004, input from patients, national guidelin
Prevent osteopenia and osteoporosis (i.e. maintain BMD T-
Prevent chronic use of analgesic medication for bone pain (
Maintain normal mobility or, if impaired at diagnosis, impr
Increase physical activity (Source: literature search)
Visceral complications Maintain spleen volume of b2 to 8 times normal after year
Maintain (near) normal liver volume after year 1–2 (Sourc
Prevent liver ﬁbrosis, cirrhosis and portal hypertension (So
Pulmonary
complications
Prevent or improve pulmonary disease, such as pulmonary
General well-being Maintain good quality of life as measured by a validated in
Maintain normal participation in school and work activitie
Minimize psychosocial burdens of life-long treatment (Sou
Achieve normal onset of puberty (Source: Pastores et al., 2
Normalize life expectancy (Source: consensus panel)
Pregnancy and delivery Prevent GD related complications during pregnancy and de
ERT = enzyme replacement therapy, SRT = substrate reduction therapy, BMD = bone minera
Please cite this article as: M. Biegstraaten, et al., Blood Cells Mol. Diseasesdeﬁciency anaemia, serum vitamin D concentrations or cholelithiasis/
cholecystitis. The detection and treatment of these conditions was con-
sidered good clinical practice rather thanmanagement goals for GD1. Fi-
nally, the beneﬁt of early detection of monoclonal gammopathy of
undetermined signiﬁcance (MGUS) and peripheral neuropathywas de-
bated. In the end, these statements were removed mainly because no
speciﬁc treatment is available forMGUS or polyneuropathy. Early detec-
tionwas therefore considered of noproven beneﬁt to thepatients. How-
ever, it was emphasized by the patient representatives that physicians
should be aware that polyneuropathy may occur, as it can be painful
and some patients may therefore beneﬁt from pain medication.
4. Discussion
With this study we developed a set of internationally supported
management goals for GD1. In general, the short-term ERT/SRT related
goals that are presented in this paper are in line with the therapeuticﬁrst 12 to 24 months of therapy (Source: Pastores et al., 2004)
Pastores et al., 2004)
w platelet numbers, platelet defects or coagulation abnormalities
e search)
s, bone infarcts and pathological fractures (Sources:
es, literature search)
scores (DEXA) of N−1) (Source: literature search)
Source: literature search)
ove mobility (Source: literature search)
1–2 (Source: Pastores et al. 2004)
es: Pastores et al., 2004, literature search)
urces: input from patients, national guidelines, literature search)
hypertension and hepatopulmonary syndrome (Adapted from: Pastores et al., 2004)
strument (Sources: input from patients, national guidelines, literature search)
s (Source: literature search)
rce: literature search)
004)
livery (Source: consensus panel)
l density, DEXA= dual energy X-ray absorptiometry, GD = Gaucher disease.
(2016), http://dx.doi.org/10.1016/j.bcmd.2016.10.008
Table 2
Management goals for Gaucher disease type 1 – related to general disease management.
Category Management goals
Long-term complications Early detection of haematological malignancies, including multiple myeloma, lymphoma and amyloidosis (Sources: input from patients, national
guidelines, literature search)
Early detection of solid tumours, including hepatocellular carcinoma and renal cell carcinoma (Sources: input from patients, national guidelines,
literature search)
Early detection of parkinsonism/Parkinson disease (Sources: input from patients, national guidelines, literature search)
Early detection of insulin resistance and type 2 diabetes mellitus (Source: literature search)
General Proper education of the patient and his family about the disease and therapy (Source: consensus panel)
Early detection of signs and symptoms indicative of GD3, such as eye movement abnormalities (Source: consensus panel)
ERT = enzyme replacement therapy, SRT = substrate reduction therapy.
Footnote: In addition to these management goals it is important to detect and treat conditions that are associated with but not speciﬁc for GD1, such as iron deﬁciency anaemia, serum
vitamin D concentrations or cholelithiasis/cholecystitis. Since this is considered good clinical practice rather than management goals for GD they are not included in this table.
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ported goals required amendment before consensus was reached. For
example, the statement ‘Lessen or eliminate bone pain within 1 to 2
years’was changed into ‘Lessen bone pain that is not related to irrevers-
ible bone disease within 1 to 2 years’, since the consensus panel indicat-
ed that a decrease can often not be achieved in case of irreversible bone
disease. New to the previously published therapeutic goals are the long-
term goals with respect to mobility, long-term liver complications and
the early detection of certain complications or associated diseases. Fur-
thermore, new goals include improvement in PROMs such as quality of
life, fatigue and social participation. This is in line with the expected
view of patients, now included in the development of the goals, who in-
dicated that quality of life, independence and absence of fatigue are of
great importance to them (see also Appendix 1). Despite the fact that
only a limited number of patients from one country (The Netherlands)
responded, we expect that these items are important to the GD1 popu-
lation as a whole.
During the consensus procedure, it was emphasized that due consid-
eration of the individual patientwas essential to any application ofman-
agement goals in clinical practice. For example, baseline disease severity
and the period between diagnosis and start of treatment bothneed to be
taken into accountwhen tailoring the goals to the individual patient. For
patients who present with irreversible manifestations such as avascular
necrosis, it is difﬁcult or even impossible to reach the mobility goals. In
this case, management may entail referral to an orthopaedic surgeon
and surgical intervention, including hip replacement when there is
pain, limited function and/or subchondral joint collapse. This is especial-
ly true for patients who were diagnosed with GD1 long before ERT was
introduced, in whom disease had progressed to a certain extent. On the
other hand, the management goals are usually easily achievable for pa-
tients with minimal organ and bone involvement and especially those
diagnosed in childhood but who have early access to speciﬁc treatment
[29]. As a result, some panellists argued for more ambitious goals (i.e.,
normalization instead of improvement). Since it is impossible to capture
all individually different situations in general goals, we decided to for-
mulate the goals in such away that they are attainable formost patients,
butwith the annotation that individualization is important. The consen-
sus panel also emphasized that it is important to rule out co-morbidities
that could explain certain diseasemanifestations such as anaemia or he-
patomegaly. Each of these items would need a proper differential diag-
nosis, especially when there is no response to therapy.
Altogether, the panel eventually reached consensus on a compre-
hensive set of management goals. To achieve this, the Delphi technique
was used which is a widely-used tool in consensus procedures [20]. By
using online surveys, a large number of experts from different countries
and with differing backgrounds could participate, thereby leading to
broad support for the ﬁnal results. Another important advantage is the
anonymity of the participants. Voting in anonymous surveys gives par-
ticipants the opportunity to give their own opinion while not being in-
ﬂuenced by hierarchical structures. However, there are some limitations
to such a procedure. First, no clear-cut guidelines exist with respect toPlease cite this article as: M. Biegstraaten, et al., Blood Cells Mol. Diseasescut-off values. In our study, we used strict criteria (at least 75% agree-
ment, and no disagreement) which sometimes resulted in the removal
of an item even if only a very limited number of participants disagreed.
We believe, however, that although these cut-off values remain arbi-
trary, strict and explicit criteria are necessary to ensure broad support
for the set of management goals. Second, the decision to remove or
amend a statement was made by the study team, and thus a certain
amount of subjectivity cannot be excluded. So far as possible to over-
come this problem, all decisionswere transparent;moreover, in the sec-
ond and third survey rounds, all accepted, amended and removed
statements were presented to the participants. Third, a face-to-face
meeting was not part of the procedure. Although a meeting might
have led to deepening of the discussions and could have reduced the in-
ﬂuence of the study team, we decided to do online surveys only to se-
cure anonymity as well as for logistic reasons.
Although recommendations on when to start treatment, which
treatmentmodality and dose to choose, and frequency and type of eval-
uations fell beyond the scope of this study, the presented management
goals can serve as a basis for improved treatment guidelines. In addition,
they can be used as a starting point for further research on the under-
standing of less speciﬁc symptoms such as fatigue, risk factors for asso-
ciated diseases such as certain malignancies and Parkinson disease/
parkinsonism, as well as the inﬂuence of ERT/SRT on long-term out-
comes, quality of life and longevity [30]. In this respect it is of impor-
tance to use or develop well-validated scoring systems that can
accommodate the collection of PROMs. Given the complexity of GD,
and limited knowledge as to long-term outcomes and PROMs, the cur-
rent set of goals should be reconsidered in the light of new evidence
as this becomes available.
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